scholarly journals Gastrointestinal cytomegalovirus disease secondary to measles in an immunocompetent infant

2021 ◽  
Vol 27 (25) ◽  
pp. 3948-3950
Author(s):  
Chao-Ming Hung ◽  
Po-Huang Lee ◽  
Hui-Ming Lee ◽  
Chong-Chi Chiu
2021 ◽  
Vol 27 (15) ◽  
pp. 1655-1663
Author(s):  
Qing-Hua Yang ◽  
Xiao-Peng Ma ◽  
Dong-Ling Dai ◽  
Da-Ming Bai ◽  
Yu Zou ◽  
...  

2020 ◽  
Vol 22 (3) ◽  
Author(s):  
Hannah Imlay ◽  
Allison O. Dumitriu Carcoana ◽  
Cynthia E. Fisher ◽  
Beatrice Wong ◽  
Robert M. Rakita ◽  
...  

1990 ◽  
Vol 10 (2) ◽  
pp. 162-166 ◽  
Author(s):  
Kevin D. Burns ◽  
Lilieth Johnson-Whittaker ◽  
Roger A. Couture ◽  
Leslie Eidus ◽  
Gary Garber

2006 ◽  
Vol 36 (2) ◽  
pp. 146-151 ◽  
Author(s):  
Tomáš Reischig ◽  
Pavel Jindra ◽  
Miroslava Švecová ◽  
Stanislav Kormunda ◽  
Karel Opatrný ◽  
...  

2000 ◽  
Vol 44 (8) ◽  
pp. 2143-2148 ◽  
Author(s):  
Mark M. Huycke ◽  
M. Tarek Naguib ◽  
Mathias M. Stroemmel ◽  
Kenneth Blick ◽  
Katherine Monti ◽  
...  

ABSTRACT Foscarnet (trisodium phosphonoformate hexahydrate) is an antiviral agent used to treat cytomegalovirus disease in immunocompromised patients. One common side effect is acute ionized hypocalcemia and hypomagnesemia following intravenous administration. Foscarnet-induced ionized hypomagnesemia might contribute to ionized hypocalcemia by impairing excretion of preformed parathyroid hormone (PTH) or by producing target organ resistance. Prevention of ionized hypomagnesemia following foscarnet administration could blunt the development of ionized hypocalcemia. To determine whether intravenous magnesium ameliorates the decline in ionized calcium and/or magnesium following foscarnet infusions, MgSO4 at doses of 1, 2, and 3 g was administered in a double-blind, placebo-controlled, randomized, crossover trial to 12 patients with AIDS and cytomegalovirus disease. Overall, increasing doses of MgSO4 reduced or eliminated foscarnet-induced acute ionized hypomagnesemia. Supplementation, however, had no discernible effect on foscarnet-induced ionized hypocalcemia despite significant increases in serum PTH levels. No dose-related, clinically significant adverse events were found, suggesting that intravenous supplementation with up to 3 g of MgSO4 was safe in this chronically ill population. Since parenteral MgSO4 did not alter foscarnet-induced ionized hypocalcemia or symptoms associated with foscarnet, routine intravenous supplementation for patients with normal serum magnesium levels is not recommended during treatment with foscarnet.


Sign in / Sign up

Export Citation Format

Share Document